BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 36902391)

  • 41. Targeted metabolomics study of early pathological features in hippocampus of triple transgenic Alzheimer's disease male mice.
    Zhao Y; Chen H; Iqbal J; Liu X; Zhang H; Xiao S; Jin N; Yao F; Shen L
    J Neurosci Res; 2021 Mar; 99(3):927-946. PubMed ID: 33197957
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The behavioral, pathological and therapeutic features of the senescence-accelerated mouse prone 8 strain as an Alzheimer's disease animal model.
    Cheng XR; Zhou WX; Zhang YX
    Ageing Res Rev; 2014 Jan; 13():13-37. PubMed ID: 24269312
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Novel biomarkers in Alzheimer's disease using high resolution proteomics and metabolomics: miRNAS, proteins and metabolites.
    Navas-Carrillo D; Rivera-Caravaca JM; Sampedro-Andrada A; Orenes-Piñero E
    Crit Rev Clin Lab Sci; 2021 May; 58(3):167-179. PubMed ID: 33137264
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Omics-based biomarkers discovery for Alzheimer's disease.
    Aerqin Q; Wang ZT; Wu KM; He XY; Dong Q; Yu JT
    Cell Mol Life Sci; 2022 Nov; 79(12):585. PubMed ID: 36348101
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Integrated metabolomics and transcriptomics reveal the neuroprotective effect of nervonic acid on LPS-induced AD model mice.
    Wang X; Li Z; Li X; Liu X; YingMao ; Cao F; Zhu X; Zhang J
    Biochem Pharmacol; 2023 Mar; 209():115411. PubMed ID: 36639003
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative.
    Veitch DP; Weiner MW; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Morris JC; Petersen RC; Saykin AJ; Shaw LM; Toga AW; Trojanowski JQ;
    Alzheimers Dement; 2019 Jan; 15(1):106-152. PubMed ID: 30321505
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A Community-Based Study Identifying Metabolic Biomarkers of Mild Cognitive Impairment and Alzheimer's Disease Using Artificial Intelligence and Machine Learning.
    Yilmaz A; Ustun I; Ugur Z; Akyol S; Hu WT; Fiandaca MS; Mapstone M; Federoff H; Maddens M; Graham SF
    J Alzheimers Dis; 2020; 78(4):1381-1392. PubMed ID: 33164929
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bridging the Gap between Alzheimer's Disease and Alzheimer's-like Diseases in Animals.
    Gołaszewska A; Bik W; Motyl T; Orzechowski A
    Int J Mol Sci; 2019 Apr; 20(7):. PubMed ID: 30987146
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The emerging role of exosomes in Alzheimer's disease.
    Zhang T; Ma S; Lv J; Wang X; Afewerky HK; Li H; Lu Y
    Ageing Res Rev; 2021 Jul; 68():101321. PubMed ID: 33727157
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Systemic and central nervous system metabolic alterations in Alzheimer's disease.
    van der Velpen V; Teav T; Gallart-Ayala H; Mehl F; Konz I; Clark C; Oikonomidi A; Peyratout G; Henry H; Delorenzi M; Ivanisevic J; Popp J
    Alzheimers Res Ther; 2019 Nov; 11(1):93. PubMed ID: 31779690
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Modeling the early stages of Alzheimer's disease by administering intracerebroventricular injections of human native Aβ oligomers to rats.
    Baerends E; Soud K; Folke J; Pedersen AK; Henmar S; Konrad L; Lycas MD; Mori Y; Pakkenberg B; Woldbye DPD; Dmytriyeva O; Pankratova S
    Acta Neuropathol Commun; 2022 Aug; 10(1):113. PubMed ID: 35974377
    [TBL] [Abstract][Full Text] [Related]  

  • 52. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.
    Jack CR; Bennett DA; Blennow K; Carrillo MC; Dunn B; Haeberlein SB; Holtzman DM; Jagust W; Jessen F; Karlawish J; Liu E; Molinuevo JL; Montine T; Phelps C; Rankin KP; Rowe CC; Scheltens P; Siemers E; Snyder HM; Sperling R;
    Alzheimers Dement; 2018 Apr; 14(4):535-562. PubMed ID: 29653606
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparing metabolomic and pathologic biomarkers alone and in combination for discriminating Alzheimer's disease from normal cognitive aging.
    Motsinger-Reif AA; Zhu H; Kling MA; Matson W; Sharma S; Fiehn O; Reif DM; Appleby DH; Doraiswamy PM; Trojanowski JQ; Kaddurah-Daouk R; Arnold SE
    Acta Neuropathol Commun; 2013 Jun; 1():28. PubMed ID: 24252434
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Alterations of Audiovisual Integration in Alzheimer's Disease.
    Liu Y; Wang Z; Wei T; Zhou S; Yin Y; Mi Y; Liu X; Tang Y
    Neurosci Bull; 2023 Dec; 39(12):1859-1872. PubMed ID: 37812301
    [TBL] [Abstract][Full Text] [Related]  

  • 55. High-Throughput Metabolomics for Discovering Potential Metabolite Biomarkers and Metabolic Mechanism from the APPswe/PS1dE9 Transgenic Model of Alzheimer's Disease.
    Yu J; Kong L; Zhang A; Han Y; Liu Z; Sun H; Liu L; Wang X
    J Proteome Res; 2017 Sep; 16(9):3219-3228. PubMed ID: 28753016
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Plasma metabolomics in early Alzheimer's disease patients diagnosed with amyloid biomarker.
    Peña-Bautista C; Roca M; Hervás D; Cuevas A; López-Cuevas R; Vento M; Baquero M; García-Blanco A; Cháfer-Pericás C
    J Proteomics; 2019 May; 200():144-152. PubMed ID: 30978462
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Purinergic receptors as potential therapeutic targets in Alzheimer's disease.
    Woods LT; Ajit D; Camden JM; Erb L; Weisman GA
    Neuropharmacology; 2016 May; 104():169-79. PubMed ID: 26519903
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Metabolomics in Alzheimer's disease: The need of complementary analytical platforms for the identification of biomarkers to unravel the underlying pathology.
    González-Domínguez R; Sayago A; Fernández-Recamales Á
    J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Dec; 1071():75-92. PubMed ID: 28189423
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparative Metabolomics Analysis Reveals Key Metabolic Mechanisms and Protein Biomarkers in Alzheimer's Disease.
    Dai Z; Hu T; Su S; Liu J; Ma Y; Zhuo Y; Fang S; Wang Q; Mo Z; Pan H; Fang J
    Front Pharmacol; 2022; 13():904857. PubMed ID: 35694256
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A new metabolomic workflow for early detection of Alzheimer's disease.
    Ibáñez C; Simó C; Barupal DK; Fiehn O; Kivipelto M; Cedazo-Mínguez A; Cifuentes A
    J Chromatogr A; 2013 Aug; 1302():65-71. PubMed ID: 23827464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.